A Tumor‐Specific Cascade Amplification Drug Release Nanoparticle for Overcoming Multidrug Resistance in Cancers | Zendy

Ye Mingzhou | Zendy; Han Yuxin | Zendy; Tang Jianbin | Zendy; Piao Ying | Zendy; Liu Xiangrui | Zendy; Zhou Zhuxian | Zendy; Gao Jianqing | Zendy; Rao Jianghong | Zendy; Shen Youqing | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

A Tumor‐Specific Cascade Amplification Drug Release Nanoparticle for Overcoming Multidrug Resistance in Cancers

Author(s) -

Ye Mingzhou,

Han Yuxin,

Tang Jianbin,

Piao Ying,

Liu Xiangrui,

Zhou Zhuxian,

Gao Jianqing,

Rao Jianghong,

Shen Youqing

Publication year - 2017

Publication title -

advanced materials

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.707

H-Index - 527

eISSN - 1521-4095

pISSN - 0935-9648

DOI - 10.1002/adma.201702342

Subject(s) - prodrug , multiple drug resistance , doxorubicin , reactive oxygen species , nad+ kinase , materials science , nanoparticle , drug resistance , cancer cell , pharmacology , cancer research , combinatorial chemistry , cancer , nanotechnology , chemotherapy , biology , chemistry , biochemistry , enzyme , microbiology and biotechnology , genetics

A cascade amplification release nanoparticle (CARN) is constructed by the coencapsulation of β‐lapachone and a reactive‐oxygen‐species (ROS)‐responsive doxorubicin (DOX) prodrug, BDOX, in polymeric nanoparticles. Releasing β‐lapachone first from the CARNs selectively increases the ROS level in cancer cells via NAD(P)H:quinone oxidoreductase‐1 (NQO1) catalysis, which induces the cascade amplification release of DOX and overcomes multidrug resistance (MDR) in cancer cells, producing a remarkably improved therapeutic efficacy against MDR tumors with minimal side effects.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research